Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
Amivantamab monotherapy in post-platinum Ex20ins NSCLC demonstrated meaningful antitumor activity in participants, and intracranial-only progression was infrequent. Treatment of brain progression with SRS while continuing amivantamab appears feasible and tolerable.
Authors
- Natasha B. Leighl (ORCID: https://orcid.org/0000-0002-3249-4602)
- Keunchil Park (ORCID: https://orcid.org/0000-0002-4846-7449)
- Meena Thayu
- Santiago Viteri (ORCID: https://orcid.org/0000-0002-7572-1123)
- Roland E. Knoblauch
- Robert W. Schnepp (ORCID: https://orcid.org/0000-0003-3217-0381)
- Pilar Garrido (ORCID: https://orcid.org/0000-0002-5899-6125)
- Joshua Bauml (ORCID: https://orcid.org/0000-0003-4193-841X)
- José Trigo (ORCID: https://orcid.org/0000-0002-4489-2683)
- Parthiv J. Mahadevia
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Se‐Hoon Lee (ORCID: https://orcid.org/0000-0002-9219-3350)
- Matthew Krebs (ORCID: https://orcid.org/0000-0001-7540-3064)
- Yichuan Xia
- Nicolas M Girard (ORCID: https://orcid.org/0000-0001-9909-2299)
- John Xie (ORCID: https://orcid.org/0000-0001-7016-6696)
- Anil Londhe
Institutions
- Yonsei University (KR)
- Samsung Medical Center (KR)
- University of Manchester (GB)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- The Christie NHS Foundation Trust (GB)
- Institut du Thorax (FR)
- Hospital Universitario Ramón y Cajal (ES)
- Institut Curie (FR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108579
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07